Imagenetix Announces Positive Safety Studies on Anti-Inflammatory Compound, 1-TDC

June 1, 2006

SAN DIEGO--(BUSINESS WIRE)--June 1, 2006--Imagenetix Inc. (OTCBB: IAGX - News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has achieved expected results in important baseline acute toxicity studies.

In the first study, CD-1 mice were administered 1-TDC orally at a dose equal to 31.5/kg body weight, or 1500 times the suggested human dose. Animals were gavaged daily for a total of seven days then euthanized using standard laboratory procedures with major organs harvested for histological examination. The findings showed no histological changes to any of the animals' main organs -- heart, kidney and liver -- and no adverse events, toxicity or abnormal behavior elicited in the animals at any time during this study.

In the second study, Golden Syrian hamsters were used to determine the potential of 1-TDC for inducing oral mucosa irritation. For all animals, one side served as control with one side exposed to the given agent. Three hamsters served as controls and were dosed with cottonseed oil as sham controls. Treatment animals were dosed with 1-TDC. All animals were dosed four times with the given agent. Exposure to each agent lasted for four hours. The cheek pouches were examined and scored for irritation prior to and after each dose. In addition, tissue samples were harvested and examined by a veterinary pathologist for histological change. The compound, 1-TDC, proved to be safe, eliciting no adverse events or histological changes in the treatment animals when compared to within animal control or sham control.

"We are very pleased with today's safety and efficacy data on 1-TDC," said Imagenetix chief executive William P. Spencer. "It is our goal to make a significant contribution with compounds that address inflammatory diseases, and these findings put us on track to accomplish that goal. The next step in this process is to select an organization that can help us move this compound through the FDA process. We believe that given the safety characteristics of 1-TDC, achieving the coveted fast-track status seems reasonable and attainable."

San Diego-based Imagenetix, Inc., www.imagenetix.net, is developing novel drugs for the treatment of inflammatory diseases. The company also develops and markets natural-based, proprietary products, including over-the-counter topical creams and skin care products, for inflammation-related markets.